ZNF710: A Potential Drug Target and Biomarker for Chronic Pain
ZNF710: A Potential Drug Target and Biomarker for Chronic Pain
Chronic pain is a significant public health issue that affects millions of people worldwide. The chronic pain population has been estimated to be between 11 and 16 million people in the United States alone, with healthcare costs associated with chronic pain estimated to be over $60 billion annually. Chronic pain can be caused by various conditions, including fibromyalgia, osteoarthritis, neuropathic pain, and cancer pain. Despite the significant impact of chronic pain on quality of life, there are limited treatment options available that can provide long-term relief. ZNF710, a zinc finger protein 710, has been identified as a potential drug target and biomarker for chronic pain.
ZNF710: A zinc finger protein 710
ZNF710 is a protein that is expressed in various tissues and cells in the body. It is a member of the ZNF family of proteins, which are known for their role in gene regulation and DNA binding. ZNF710 is unique due to its potential to interact with other proteins and molecules, including transcription factors, to regulate gene expression and cell function.
ZNF710 has been shown to play a role in pain signaling and regulation. It has been shown to interact with TrkA, a protein that is involved in pain modulation. ZNF710 has also been shown to regulate the activity of other pain-related genes, including CSSA, a gene that encodes a protein involved in pain perception and neuropeptide synthesis.
Potential drug targeting
The identification of ZNF710 as a potential drug target for chronic pain is based on its unique structure and its involvement in pain signaling and regulation. ZNF710 has been shown to interact with multiple proteins and molecules involved in pain signaling and regulation, making it an attractive target for drug development.
One approach to targeting ZNF710 is to use small molecules that can modulate its activity. Small molecules that can interact with ZNF710 include inhibitors of protein tyrosine kinase (PTK), a protein that is involved in cell signaling, and inhibitors of the protein kinase B (PKB), which is involved in cell signaling and pain modulation. Additionally, small molecules that can modulate ZNF710 activity can be designed to specifically target its active site, such as inhibitors of the nucleotide binding oligomerization domain (NBO), which is a structural domain found in proteins that bind to DNA.
Biomarker potential
ZNF710 has also been identified as a potential biomarker for chronic pain. The identification of ZNF710 as a potential biomarker is based on its expression and its potential to be modified by small molecules. ZNF710 has been shown to be expressed in various tissues and cells involved in pain signaling and regulation, including brain, spinal cord, and peripheral tissues. Additionally, ZNF710 has been shown to be involved in pain signaling and regulation, which makes it a potential biomarker for chronic pain.
Conclusion
ZNF710 is a protein that has been shown to play a role in pain signaling and regulation. Its unique structure and its involvement in multiple pain-related genes make it an attractive target for drug development. The identification of ZNF710 as a potential drug target and biomarker for chronic pain opens up new avenues for research and treatment options. Further studies are needed to fully understand the role of ZNF710 in pain signaling and regulation, and to develop safe and effective treatments for chronic pain.
Protein Name: Zinc Finger Protein 710
Functions: May be involved in transcriptional regulation
The "ZNF710 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ZNF710 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
ZNF711 | ZNF713 | ZNF714 | ZNF716 | ZNF717 | ZNF718 | ZNF721 | ZNF723 | ZNF724 | ZNF726 | ZNF727 | ZNF728 | ZNF729 | ZNF730 | ZNF732 | ZNF734P | ZNF735 | ZNF736 | ZNF737 | ZNF738 | ZNF74 | ZNF740 | ZNF746 | ZNF747 | ZNF749 | ZNF750 | ZNF75A | ZNF75CP | ZNF75D | ZNF76 | ZNF761 | ZNF763 | ZNF764 | ZNF765 | ZNF766 | ZNF767P | ZNF768 | ZNF77 | ZNF770 | ZNF771 | ZNF772 | ZNF773 | ZNF774 | ZNF775 | ZNF776 | ZNF777 | ZNF778 | ZNF780A | ZNF780B | ZNF781 | ZNF782 | ZNF783 | ZNF784 | ZNF785 | ZNF786 | ZNF787 | ZNF788P | ZNF789 | ZNF79 | ZNF790 | ZNF790-AS1 | ZNF791 | ZNF792 | ZNF793 | ZNF799 | ZNF8 | ZNF8-ERVK3-1 | ZNF80 | ZNF800 | ZNF804A | ZNF804B | ZNF805 | ZNF807P | ZNF808 | ZNF81 | ZNF812P | ZNF813 | ZNF814 | ZNF815P | ZNF816 | ZNF816-ZNF321P | ZNF818P | ZNF821 | ZNF823 | ZNF826P | ZNF827 | ZNF829 | ZNF83 | ZNF830 | ZNF831 | ZNF833P | ZNF835 | ZNF836 | ZNF837 | ZNF839 | ZNF839P1 | ZNF84 | ZNF840P | ZNF841 | ZNF843
